Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo

Launched by ASSIUT UNIVERSITY · Jul 7, 2023

Keywords

ClinConnect Summary

The clinical trial is studying a new treatment for non-segmental vitiligo, a skin condition that causes loss of pigmentation and results in white patches on the skin. This trial will compare the effects of a combination treatment using a topical medication called baricitinib along with a special light therapy (308-nm monochromatic excimer light) against using the light therapy alone. The goal is to see if the combination treatment is safe and more effective for improving skin color in people with this condition.

To participate in the trial, you need to be at least 12 years old and have active non-segmental vitiligo that affects at least 1% of your body, with noticeable areas on your face. You should not have used any other treatments for vitiligo in the two months before the study, and certain other health conditions may exclude you from participating. If you join the trial, you can expect to receive either the combination treatment or the light therapy alone, and the researchers will monitor your progress closely to assess how well the treatments work. This study is not yet recruiting participants, so it’s a great opportunity to learn more about potential future treatments for vitiligo.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients of age above 12y old. Patients with active non-segmental vitiligo, having minimum of 1% body surface area (BSA) affected, with significant facial involvement (≥0.5% of the BSA on the face).
• • Co-operative patients, agree to join the study and will give consent.
• Exclusion Criteria:
• • Patients receiving phototherapy or any form of systemic therapy for vitiligo during the previous 2 months preceding the study.
• • Patients applying topical medications to the face during the last month before the study Pregnant or lactating females. Patients with history of allergy to JAK inhibitors, or history of photosensitivity or post inflammatory hyperpigmentation.
• • Patients with active skin infection at site of treatment.